044sek
-0,7 %
Date:2025-05-14Time:16:43:06Latest report:Q4-2024List:First NorthTicker:SPRINT
Market Cap:46 msekEnterprise Value:21 msekNet Sales:65,6 msekEarnings:-18,3 msekEmployees:0ISIN:SE0006343745

Ratios

10-year key figure history for Sprint Bioscience turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Sprint Bioscience with index and moving average MA50 and MA200.

Stockprice:0,44
MA50:0,78
MA200:1,34
Price/MA200:-68,9 %
RSI (14):21,9
Price/MA50:-46,5 %

Description

Sprint Bioscience is a research company. The company develops pharmaceutical candidates that alone or in combination with other pharmaceuticals can fight cancer. The company has a project portfolio focused on attacking parts of cancer cell processes. The company's business model is based on developing projects parallel in the preclinical phase to subsequently enter into licensing agreements with the global pharmaceutical industry. The company was founded in 2009 and is headquartered in Huddinge.

Biotechnology